TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06658106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thera-Band Elastic Band-Assisted Progressive Resistance Training
Description: Thera-Band Elastic Band-Assisted Progressive Resistance Training: This intervention involves a structured exercise program using Thera-Band elastic bands for resistance training, conducted three times a week for 12 weeks. Each session lasts approximately 50 minutes and includes exercises targeting major muscle groups, such as upper arms, shoulders, chest, lumbar, and lower limbs. Participants will perform each exercise for 8-12 repetitions in 2-3 sets with 1-minute intervals, aiming for an intensity of 60%-80% of their maximum heart rate. The program is designed to improve strength, balance, and overall physical function, thereby reducing frailty in older adults with diabetes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Diabetes Management
Description: Conventional Diabetes Management: Participants in this arm will receive standard care for diabetes management, which includes health education covering diet, medication adherence, exercise recommendations, and routine health monitoring. This arm serves as a comparator to assess the effectiveness of the progressive resistance training intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Diabetes Management
Description: Conventional Diabetes Management: Participants in this arm will receive standard care for diabetes management, which includes health education covering diet, medication adherence, exercise recommendations, and routine health monitoring. This arm serves as a comparator to assess the effectiveness of the progressive resistance training intervention.
Study: NCT06661018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q 10
Description: participant will receive STEMI standard treatment plus oral Coenzyme Q10 (chewable tablet) 100 mg / 12 hours for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participant will receive STEMI standard treatment plus placebo /12 hours for 8 weeks
Study: NCT06608238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-MNA 200 mcg
Description: D-MNA , (doxorubicin) patch, 200 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-MNA 100 mcg
Description: D-MNA (doxorubicin) patch, 100 mcg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: P-MNA patch, placebo
Study: NCT06592014

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lithium aspartate
Description: Lithium aspartate with dosage adjusted to serum lithium level 0.25-0.50mmol/L
Study: NCT06658353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC004 Capsules
Description: VC004 Capsules BID
Study: NCT06662136

Intervention type: BEHAVIORAL
Intervention: motivational interview
Description: Participants in the experimental group will be given motivational interviews about HPV at 4 different times and will also be given an educational brochure.

Intervention type: OTHER
Intervention: Control
Description: Participants in the control group will not receive any intervention.
Study: NCT06659900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CORE Plus (+)
Description: CORE PLUS intervention will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials, a voucher for a medication starter kit PLUS support from a Community Health Advisor who will serve as a connector to primary care for HTN management and send reminder text messages.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CORE
Description: CORE intervention will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials and a voucher for a medication starter kit
Study: NCT06659471

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.76% Sodium Monofluorophosphate Dentifrice
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.454% Stannous Fluoride Dentifrice
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.454% Stannous Fluoride Dentifrice
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.454% Stannous Fluoride Dentifrice
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Study: NCT05625789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postural control (weight shift) training
Description: Visual cues to improve amplitude of weight shift prior to initiating gait.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postural control (weight shift) training
Description: Visual cues to improve amplitude of weight shift prior to initiating gait.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Steady state gait training
Description: Auditory cues are provided to increase amplitude of movement (e.g., step length) during continuous walking, to determine its effects on gait initiation amplitude of movement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Steady state gait training
Description: Auditory cues are provided to increase amplitude of movement (e.g., step length) during continuous walking, to determine its effects on gait initiation amplitude of movement.
Study: NCT06527144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3mg TQC3721 Suspension for Inhalation
Description: TQC3721 suspension for inhalation is target inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6mg TQC3721 Suspension for Inhalation
Description: TQC3721 suspension for inhalation is target inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TQC3721 suspension for inhalation
Description: Placebo without active drug substance.
Study: NCT06412978

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: absorbable subcuticular polyglycolic acid staples (INSORB)
Description: Insorb absorbable staples are used for skin closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subcuticular, polyglecaprone suture (Monocryl)
Description: Monocryl absorbable staples are used for skin closure
Study: NCT06623994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task sharing with Epilepsy Medical Record Systems
Description: Training multiple cadres of healthcare workers in epilepsy treatment and management to enable a team-based approach to address access to care. Task sharing will be supported by epilepsy medical records system with patient tracking data to support care retention
Study: NCT06239220

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 t-haNK
Description: Allogeneic, stable, clonal natural killer cell line product, via intravenous infusion (into the vein) per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 t-haNK
Description: Allogeneic, stable, clonal natural killer cell line product, via intravenous infusion (into the vein) per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Epidermal growth factor receptor, via intravenous (into the vein) infusion per institutional standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Epidermal growth factor receptor, via intravenous (into the vein) infusion per institutional standard of care.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Recombinant human superagonist, via subcutaneous injection (under the skin) per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Recombinant human superagonist, via subcutaneous injection (under the skin) per protocol.
Study: NCT05638802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-7011a
Description: 20 mg/kg intravenous dose to be administered every 4 weeks at baseline (Day 1), Day 29, and Day 57

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline intravenous solution administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
Study: NCT05051293

Intervention type: OTHER
Intervention: serum concentration of estrogen (E1 and E2) and testosterone ratio measurement
Description: To measure the serum concentration of estrogen (E1 and E2) and testosterone ratio in all male cirrhosis patients

Intervention type: OTHER
Intervention: serum concentration of estrogen (E1 and E2) and testosterone ratio measurement
Description: To measure the serum concentration of estrogen (E1 and E2) and testosterone ratio in all male cirrhosis patients
Study: NCT06793293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High level laser
Description: It will be consisted of twenty-five postoperative cesarean section women and will be treated by medical treatment (Non-steroidal anti- inflammatory drugs and antibiotics) in addition to High level laser for 5 minutes on days 1 st , 2 nd , and 3 rd , after cesarean section (3 sessions)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-steroidal anti- inflammatory drugs and antibiotics
Description: It will be consisted of twenty-five postoperative cesarean section women and will be treated by medical treatment (Non-steroidal anti- inflammatory drugs and antibiotics) only.
Study: NCT06795828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional support group
Description: Women who met the inclusion criteria and volunteered to participate in the study and were provided emotional support were administered the Personal Information Form, Visual Analog Scale, State Anxiety Inventory and Surgical Fear Scale via face-to-face interview method on the first day of their hospitalization before the caesarean section (pre-test). This application lasted 15-20 minutes. Enter a brief, descriptive title for this arm of the study.
Study: NCT06795997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tax Conditions
Description: Participants will make hypothetical purchases of tobacco products to use throughout the next 7 days. Participants will complete a total of 21 purchasing trials each for 7 days' worth of products. They will be exposed to 4 conditions with 5 trials each, where products will increase in price: Tobacco Parity, Nicotine-Content, Harm- Reduction, and Modified Risk Tobacco Product-related taxes.
Study: NCT06506201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Velys hip navigation
Description: Computer assisted surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Velys hip navigation
Description: Computer assisted surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Velys hip navigation
Description: Computer assisted surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: surgery without navigation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: surgery without navigation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: surgery without navigation
Study: NCT04940351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GROUP - A: PIEZOCISION GROUP
Description: This group will receive piezocisions after placement of initial arch wire, in between the roots of mandibular anteriors (in a vertical line) i.e., between mandibular canine and lateral incisors bilaterally, lateral incisors and central incisors bilaterally and between two cental incisors with the help of piezotome. These piezocisions will be performed on the labial cortical bone only, 4mm below the interdental papilla under 2% lidocaine with 1:100,000 epinephrine and with standard asepsis, and gingival overlying will be incised first with blade number 15 in a Bard Parker handle. A piezosurgical microsaw with piezosurgical drill will be placed over that incision with irrigation. Then, vertical 5- to 8-mm and 3mm deep corticotomies will be perform using periapical radiographs as a guide to avoid penetrating into the adjacent roots. No subsequent sutures required.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GROUP- B: MICRO-OSTEOPERFORATION GROUP
Description: This group will receive MOPs after initial arch wire placement. These MOPs will be performed under local anesthesia with standard asepsis, using a self drilling 1.6mm x 8mm orthodontic mini-implants and mini-implant screw driver and no flap will be raised. MOP's will be placed on five sites i.e., interproximally between mandibular canine and lateral incisors bilaterally, central incisor and lateral incisor bilaterally and between two central incisors. Each site will receive two MOP's, first 2mm apical to alveolar crest and second 2mm below the first in a vertical line and 2mm deep into the bone. Then the mini-implant will be removed by rotating the screw driver anticlockwise and pressure will be applied to achieve hemostasis.
Study: NCT04882540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brivaracetam
Description: * Pharmaceutical form: Film-coated tablets~* Concentration: 100 mg tablets~* Route of administration: Oral use
Study: NCT06795997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Condition
Description: Participants will make hypothetical purchases of tobacco products to use throughout the next 7 days. Participants will complete a total of 21 purchasing trials each for 7 days' worth of products. They will be exposed to a control trial.
Study: NCT06797453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Medical Visits
Description: Shared group medical visits over eight weeks and two cooking classes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Full Plate Living
Description: Online modules teaching how a high-fiber diet can lead to more energy, lower cholesterol, better blood sugar, and easier weight loss.
Study: NCT06793345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity intermittent walking training
Description: The intensity of the training is 60 to 80% of 6MWTdistance.
Study: NCT06793098

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of kisspeptin concentration
Description: Measurement of kisspeptin concentration in fasting venous blood serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of kisspeptin concentration
Description: Measurement of kisspeptin concentration in fasting venous blood serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of kisspeptin concentration
Description: Measurement of kisspeptin concentration in fasting venous blood serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of ghrelin concentration
Description: Measurement of ghrelin concentration in fasting venous blood serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of ghrelin concentration
Description: Measurement of ghrelin concentration in fasting venous blood serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of ghrelin concentration
Description: Measurement of ghrelin concentration in fasting venous blood serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of zonulin concentration
Description: Measurement of zonulin concentration in fasting venous blood serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of zonulin concentration
Description: Measurement of zonulin concentration in fasting venous blood serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of zonulin concentration
Description: Measurement of zonulin concentration in fasting venous blood serum
Study: NCT06793930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A tailored, optimised, and person-centred critical pathway to promote sustainable lifestyle modification
Description: The TOP-S programme is a nurse-led intervention promoting the maintenance of lifestyle modification

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Brief advice
Description: once-off brief lifestyle advice lasting for 15 minutes
Study: NCT06785025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-Based Dance Fitness Intervention
Description: This group-based intervention will be conducted with women only. Women enrolled in the study and assigned to the intervention condition will complete 2 30-minute classes per week for 6 weeks. All classes will be held on a university campus and take place during the lunch hour (12:30-1pm). All classes will be led by a certified group fitness leader who is a member of the research team.
Study: NCT06795425

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postbiotic Active Lifestyle Blend
Description: The active intervention, Postbiotic Active Lifestyle Blend, containing a heat-treated blend of bacterial strains; 2 capsules per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo intervention contains no active ingredients and consists of maltodextrin as an inactive ingredient. The capsule matches the appearance and dosage form of the active intervention.
Study: NCT06792786

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ctDNA detection
Description: dynamically monitor the changes of ctDNA in patients with esophageal cancer Radiation: Radiotherapy 95% PTV50-50.4Gy/25-28fractions, 1.8-2Gy/1 fractions; 5 days a week; 6 weeks. Chemotherapy:weekly paclitaxel (50mg/m²) in combination with carboplatin (AUC=2) chemotherapy, a total of 4-5 cycles.~Other Names:~Intensity-modulated radiotherapy (IMRT) Drug: Toripalimab Toripalimab (240 mg, intravenously infused) will be administered as the maintenance treatment every 3 weeks within 4 weeks after the completion of radiotherapy for 1 years or until progression, intolerable toxicity, or physician/patient decision~Other Names:~Immunotherapy ctDNA detection: The first tissue and blood ctDNA test (T0) before treatment is based on next generation sequencing (NGS) technology, and ctDNA test is based on tumor- prior analysis informed assays method. Blood ctDNA testing after chemoradiotherapy was performed every 3 months
Study: NCT06794060

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C (Ascorbic Acid)
Description: Participants swallow synthetic vitamin C tablets 500mg with water, twice a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C (Ascorbic Acid)
Description: Participants swallow naturral vitamin C tablets 500mg with water, twice a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants swallow tablets with the same texture, flavor, and appearance as the experimental group 500mg with water, twice a day.
Study: NCT06797544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 0.5%
Description: Intralesional levofloxacin (5 mg/ml, 100 ml, Tavanic®, Sanofi, France) will be injected into each lesion based on its size (5 mg/cm2). The infiltration of intralesional dose will be given once weekly for up to 6 weeks. Treatment will be stopped in patients cured before 6 weeks of treatment, and patients were only asked to come for lesion assessment. A fine insulin needle will be used to infiltrate the lesion.~The lesion will be thoroughly infiltrated with the drug solution until the base will be completely blanched. Depending on the lesion size, the amount of solution required ranged from 0.2 to 4.0 ml per lesion. No local anesthesia was added. The solutions were injected intralesionally and not subcutaneously.
Study: NCT06795074

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Optilume
Description: Dilatation with drug-coated balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UroMax Ultra
Description: Dilatation with non-coated balloon
Study: NCT06797674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7602
Description: Capsule
Study: NCT06491641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care based on Kolcaba's comfort theory
Description: During the application process, the babies in the experimental group will receive care based on Kolcaba's comfort theory during their stay in intensive care.
Study: NCT06437288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Receive an intravenous infusion of hematoporphyrin injection
Study: NCT06302400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 166Holmium microspheres (QuiremSpheres®)
Description: QuiremSpheres® are a biocompatible microsphere that contain the radionuclide holmium-166 (166Ho), which emits gamma-radiation (81 keV) and high-energy (1.81 MeV) beta-particles.
Study: NCT05308017

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Richard Wolf 24F Laser scope
Description: 24F Laser with HoLEP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Karl Storz 28F Laser Scope
Description: 28 F Laser with HoLEP
Study: NCT06108193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical minoxidil in Acne Vulgaris
Description: Split face: 2% or 5% topical minoxidil solution applied and no treatment Description: Subjects will apply the 2% or 5% topical minoxidil solution to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face twice a day for 4 weeks.
Study: NCT05898308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiTUXimab Injection
Description: Patients assigned to the personalized maintenance treatment will be treated by additional RITUXIMAB injection depending on anti-Dsg Abs levels.
Study: NCT06257667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Support
Description: Treatment with High Flow Nasal Cannula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Support
Description: Treatment with High Flow Nasal Cannula
Study: NCT04331340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist review of LUTS
Description: Pharmacist review and recommendations, including education, behaviour, lifestyle, or medications

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist Provision of healthy aging leaflets
Description: Pharmacist will inquire about presence of LUTS and provide patient with healthy aging leaflets
Study: NCT06797674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Tablet
Study: NCT06795126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Little NIRVANA
Description: Augmented reality (AR) digital solution where children interact with the game using a magic wand